1,101 posts by 291 firms and lawyers
Cannabis law explained by the lawyers who practise it: analysis and commentary from law firms around the world, with the Cannabis Law Journal.
Cannabis companies are used to hearing “no” from the tax system, so a recent ruling from the Colorado Department of Revenue stands out. In Private Letter Ruling 26-005, issued in July 2026, the Department considered whether a…
Since the April 2026 filing season, the landscape surrounding Section 280E of the Internal Revenue Code has continued to evolve in significant ways. , d/b/a Ultra Health v.
On April 23, 2026, the Department of Justice and the Drug Enforcement Administration issued an order moving medical marijuana subject to a state license from Schedule I to Schedule III of the Controlled Substances Act.
Rescheduling did not just change tax treatment and licensing options for cannabis operators. It also changed the assumptions baked into thousands of existing cannabis contracts.
On April 23, 2026, the DOJ and DEA issued a final order rescheduling certain marijuana products from Schedule I to Schedule III of the Controlled Substances Act. The order is subject to litigation, but it remains in effect for…
Article by: Ivy Perez-Bader, Raza Lawrence, Jana Weltzin, Greg Cowan, and Tom Zuber
The federal regulatory landscape governing cannabis in the United States is undergoing its most significant transformation in over fifty years.
Marijuana’s proposed move from Schedule I to Schedule III under the Controlled Substances Act has renewed focus on what rescheduling could mean for marijuana-related businesses (MRBs) and the financial institutions that serve…
The rescheduling of certain cannabis products to Schedule III represents a meaningful shift in federal cannabis policy and offers long-awaited tax relief for portions of the industry.
On April 23, 2026, as we discussed in our prior client alert, the Department of Justice issued a Final Order immediately placing cannabis “subject to a state medical marijuana license” in Schedule III of the Controlled Substances…
This is the second of 13 posts describing the impacts of marijuana’s rescheduling. An homage to Phish’s historic run at Madison Square Garden in the Summer of 2017, Budding Trends Baker’s Dozen will address how rescheduling…
S. Department of Justice (DOJ) has announced a landmark shift in federal cannabis policy, reclassifying certain cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).
Medical cannabis products moved to Schedule III and to become fully legal with DEA Registration; Possibility for Adult-Use Rescheduling in Upcoming Hearing
After years of false starts, stalled hearings, a retired judge, a fired attorney general, and a president who last weekend told officials to stop “slow-walking” on cannabis, we finally have something to talk about.
Schedule I → Schedule III: A Landmark Policy Shift with Important Limits
In the last year or two, we have seen a growing number of marijuana businesses take the position that IRC 280E no longer applies to them. Some of these businesses have taken that position in consultation with lawyers and CPAs.
After more than fifty years of classification alongside heroin and LSD, cannabis may soon occupy the same legal category as ketamine and Tylenol with codeine. S. cannabis industry.
S. Attorney General to reclassify cannabis from a Schedule I controlled substance to a Schedule III controlled substance under the Controlled Substances Act.
” Currently, marijuana is a Schedule I drug under the Controlled Substances Act (CSA). The Drug Enforcement Agency began the rescheduling process under President Biden, but that process was uncompleted when President Biden left…
On Dec. 18th, President Trump signed an executive order directing the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act.